Celecoxib for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This research study tests whether adding a drug called celecoxib (an anti-inflammatory pill) can help treat early-stage triple-negative breast cancer after surgery, before or during radiation therapy. You may be eligible if your cancer was removed cleanly and you do not have other health issues like stomach ulcers, kidney problems, or a history of allergic reactions to certain pain relievers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- You have early-stage triple-negative breast cancer (confirmed by a biopsy).
- Your cancer has not spread to distant parts of the body (no metastasis).
- You had surgery to remove the tumor, and the edges were clear of cancer (negative margins).
- In the last 6 months, you have not had a stomach ulcer, kidney disease, liver disease, or heart failure.
- You are not currently taking any anti-inflammatory pain relievers (like ibuprofen or naproxen) and have no history of allergy to celecoxib, sulfa drugs, aspirin, or similar medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.